Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors

The mutation-driven transformation of clinical anti-androgen drugs into agonists of the human androgen receptor (AR) represents a major challenge for the treatment of prostate cancer patients. To address this challenge, we have developed a novel class of inhibitors targeting the DNA-binding domain (...

Descripción completa

Detalles Bibliográficos
Autores principales: Radaeva, Mariia, Li, Huifang, LeBlanc, Eric, Dalal, Kush, Ban, Fuqiang, Ciesielski, Fabrice, Chow, Bonny, Morin, Helene, Awrey, Shannon, Singh, Kriti, Rennie, Paul S., Lallous, Nada, Cherkasov, Artem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497135/
https://www.ncbi.nlm.nih.gov/pubmed/36139361
http://dx.doi.org/10.3390/cells11182785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497135/
https://www.ncbi.nlm.nih.gov/pubmed/36139361
http://dx.doi.org/10.3390/cells11182785

Ejemplares similares